Aurion Biotech, a company focused on regenerative medicine, has announced encouraging findings from its Phase 1/2 CLARA trial, which evaluated the groundbreaking therapy AURN001 for patients suffering from corneal endothelial disease. The trial, which sought to assess the safety and efficacy of AURN001, demonstrated significant positive outcomes after 12 months of treatment. This therapy, which combines human corneal endothelial cells with the Y-27632 rho-kinase inhibitor, shows promise for restoring vision in patients affected by corneal edema due to endothelial dysfunction.
### Trial Details and Outcomes
The Phase 1/2 CLARA trial enrolled 97 participants across 20 clinical sites in the United States and Canada. Results were presented during the American Academy of Ophthalmology (AAO) meeting held in Orlando, Florida. Patients were divided into several groups receiving varying doses of AURN001, and the study’s primary endpoint focused on the improvement of best corrected visual acuity (BCVA) by at least 15 letters from baseline after six months. Notably, the high-dose group exhibited a remarkable 65% success rate in achieving this improvement, starkly contrasted with the 0% success rate of the control group receiving only the Y-27632 treatment.
Data showed that those in the high-dose category experienced a mean improvement of 12.5 letters in BCVA, alongside a significant reduction in central corneal thickness by 23.2 µm. These results suggest both strong efficacy and safety for the treatment, as no serious adverse events or graft rejections were reported throughout the study.
### Expert Commentary and Future Steps
Dr. Edward J. Holland, the Chief Medical Officer at Aurion Biotech, remarked on the trial’s outcomes, emphasizing that the results reinforce the efficacy of AURN001 across diverse patient demographics. He expressed optimism about the upcoming pivotal Phase 3 trial scheduled for the first half of 2026, which aims to continue exploring this innovative cell therapy’s potential to significantly impact vision restoration for patients suffering from corneal endothelial blindness.
In agreement, Dr. W. Barry Lee, a cornea specialist and President of the Cornea Society, highlighted the significance of achieving all primary, secondary, and exploratory endpoints in this trial, asserting that the safety profile of AURN001 would instill confidence among clinicians as the research progresses.
### Regulatory Designations and Manufacturing Potential
In the United States, Aurion Biotech has received Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy Designation (BTD) for AURN001, recognizing its potential to address corneal endothelial diseases. Unlike traditional treatments that face limitations due to donor shortages, AURN001 utilizes cultured human corneal endothelial cells. Each donor line can potentially yield up to 1,000 therapeutic doses, a feature that could revolutionize treatment accessibility for millions suffering from vision loss.
With the promising results from the CLARA trial and the anticipated Phase 3 study, Aurion Biotech is poised to make significant strides in the field of ophthalmology, bringing hope to those affected by corneal diseases. For more information on their ongoing initiatives, visit www.aurionbiotech.com and follow their updates on LinkedIn.
Related
